" class="no-js "lang="en-US"> REGENXBIO - Medtech Alert
Thursday, March 28, 2024
REGENXBIO | Pharmtech Focus

REGENXBIO

About REGENXBIO

REGENXBIO

REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO’s mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO’s NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees.

Related Story

REGENXBIO Announces Phase I/II Trial of RGX-202, a Novel Gene Therapy Candidate for Duchenne Muscular Dystrophy

January 23 2023

REGENXBIO today announced that the Phase I/II AFFINITY DUCHENNE™ trial of RGX-202 for the treatment […]

AbbVie and REGENXBIO Announce Eye Care Collaboration

September 14 2021

AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced a partnership to develop and […]